Skip to main content
Journal of Virology logoLink to Journal of Virology
. 1992 May;66(5):2664–2669. doi: 10.1128/jvi.66.5.2664-2669.1992

Specific lysis of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones.

Z Huang 1, A Vafai 1, J Lee 1, R Mahalingam 1, A R Hayward 1
PMCID: PMC241020  PMID: 1348545

Abstract

Varicella-zoster virus (VZV)-specific CD4-positive T cells are known to lyse targets expressing VZV antigen, but little is known of the glycoprotein specificity or phenotype of these cells. To test the ability of T cells to distinguish between gpI and gpIV (which share an antibody-defined epitope), we prepared clones from blood from four healthy individuals by limiting dilution. Among 68 T-cell clones from four donors which were VZV specific in tests of proliferation, 30 lysed autologous Epstein-Barr virus-transformed lymphoblasts which had been superinfected with a recombinant vaccinia virus which included the whole VZV gpI sequence. These clones were characterized as major histocompatibility complex class II restricted by inhibition of their cytotoxicity with HLA-DR and CD4 monoclonal antibodies. Twenty-one clones lysed targets expressing gpIV. Fifteen of these clones lysed targets expressing gpI and gpIV. Four clones with gpI-gpIV specificity were examined in detail, and their dual specificity was confirmed by cold target inhibition. These four clones failed to kill target cells infected with a mutant gpIV recombinant vaccinia virus from which amino acid residues 212 to 354 had been deleted. This region includes one of the two gpIV decapeptides which have 50% homology with amino acids 111 to 121 of gpI. Our data confirm that T-cell-receptor-associated structures are required for specific lysis of VZV targets and indicate that (i) gpI-specific CD4 cytotoxic T cells outnumber gpIV-specific T cells in blood and (ii) 50% of gpI-specific T-cell clones also lyse gpIV-expressing targets.

Full text

PDF
2664

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arvin A. M., Sharp M., Smith S., Koropchak C. M., Diaz P. S., Kinchington P., Ruyechan W., Hay J. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol. 1991 Jan 1;146(1):257–264. [PubMed] [Google Scholar]
  2. Bennink J. R., Yewdell J. W., Smith G. L., Moss B. Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes. J Virol. 1986 Mar;57(3):786–791. doi: 10.1128/jvi.57.3.786-791.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bergen R. E., Diaz P. S., Arvin A. M. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J Infect Dis. 1990 Nov;162(5):1049–1054. doi: 10.1093/infdis/162.5.1049. [DOI] [PubMed] [Google Scholar]
  4. Cabirac G., Gilden D., Wellish M., Vafai A. Expression of varicella-zoster virus glycoprotein I in cells infected with a vaccinia virus recombinant. Virus Res. 1988 May;10(2-3):205–213. doi: 10.1016/0168-1702(88)90016-0. [DOI] [PubMed] [Google Scholar]
  5. Chilmonczyk B. A., Levin M. J., McDuffy R., Hayward A. R. Characterization of the human newborn response to herpesvirus antigen. J Immunol. 1985 Jun;134(6):4184–4188. [PubMed] [Google Scholar]
  6. Cooper E. C., Vujcic L. K., Quinnan G. V., Jr Varicella-zoster virus-specific HLA-restricted cytotoxicity of normal immune adult lymphocytes after in vitro stimulation. J Infect Dis. 1988 Oct;158(4):780–788. doi: 10.1093/infdis/158.4.780. [DOI] [PubMed] [Google Scholar]
  7. Davison A. J., Waters D. J., Edson C. M. Identification of the products of a varicella-zoster virus glycoprotein gene. J Gen Virol. 1985 Oct;66(Pt 10):2237–2242. doi: 10.1099/0022-1317-66-10-2237. [DOI] [PubMed] [Google Scholar]
  8. Diaz P. S., Smith S., Hunter E., Arvin A. M. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol. 1989 Jan 15;142(2):636–641. [PubMed] [Google Scholar]
  9. Hayward A. R., Burger R., Scheper R., Arvin A. M. Major histocompatibility complex restriction of T-cell responses to varicella-zoster virus in guinea pigs. J Virol. 1991 Mar;65(3):1491–1495. doi: 10.1128/jvi.65.3.1491-1495.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hayward A. R., Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol. 1987 Mar;7(2):174–178. doi: 10.1007/BF00916011. [DOI] [PubMed] [Google Scholar]
  11. Hayward A. R., Pontesilli O., Herberger M., Laszlo M., Levin M. Specific lysis of varicella zoster virus-infected B lymphoblasts by human T cells. J Virol. 1986 Apr;58(1):179–184. doi: 10.1128/jvi.58.1.179-184.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hayward A. R. T-cell responses to predicted amphipathic peptides of varicella-zoster virus glycoproteins II and IV. J Virol. 1990 Feb;64(2):651–655. doi: 10.1128/jvi.64.2.651-655.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hayward A., Giller R., Levin M. Phenotype, cytotoxic, and helper functions of T cells from varicella zoster virus stimulated cultures of human lymphocytes. Viral Immunol. 1989 Fall;2(3):175–184. doi: 10.1089/vim.1989.2.175. [DOI] [PubMed] [Google Scholar]
  14. Keller P. M., Lonergan K., Neff B. J., Morton D. A., Ellis R. W. Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods. 1986 Sep;14(2):177–188. doi: 10.1016/0166-0934(86)90048-0. [DOI] [PubMed] [Google Scholar]
  15. Slørdahl S. H., Wiger D., Strømøy T., Degre M., Thørsby E., Lie S. O. Vaccination of children with malignant disease against varicella. Postgrad Med J. 1985;61 (Suppl 4):85–92. [PubMed] [Google Scholar]
  16. Vafai A., Jensen K., Kubo R. Existence of similar antigenic-sites on varicella-zoster virus gpI and gpIV. Virus Res. 1989 Aug;13(4):319–336. doi: 10.1016/0168-1702(89)90077-4. [DOI] [PubMed] [Google Scholar]
  17. Vafai A., Wroblewska Z., Mahalingam R., Cabirac G., Wellish M., Cisco M., Gilden D. Recognition of similar epitopes on varicella-zoster virus gpI and gpIV by monoclonal antibodies. J Virol. 1988 Aug;62(8):2544–2551. doi: 10.1128/jvi.62.8.2544-2551.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Vafai A., Yang W. N. Neutralizing antibodies induced by recombinant vaccinia virus expressing varicella-zoster virus gpIV. J Virol. 1991 Oct;65(10):5593–5596. doi: 10.1128/jvi.65.10.5593-5596.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Watson B., Keller P. M., Ellis R. W., Starr S. E. Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity. J Infect Dis. 1990 Oct;162(4):794–799. doi: 10.1093/infdis/162.4.794. [DOI] [PubMed] [Google Scholar]
  20. Zaia J. A., Leary P. L., Levin M. J. Specificity of the blastogenic response of human mononuclear cells to herpesvirus antigens. Infect Immun. 1978 Jun;20(3):646–651. doi: 10.1128/iai.20.3.646-651.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES